Adocia's Combination Insulin Formulation Shows Positive Results in Phase I/II Trial - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Adocia's Combination Insulin Formulation Shows Positive Results in Phase I/II Trial


Adocia, a biotech company that specializes in the development of approved protein formulations, has reported positive results for the first clinical trial of its combination insulin formulation of fast- and long-acting insulin in patients with type I diabetes. The formulation, BioChaperone Combo, utilizes Adocia's proprietary technology to solubilize the gold standard basal insulin analog glargine (Lantus, Sanofi) at physiological pH, allowing combination in solution with the rapid-acting insulin analog, lispro (Humalog, Eli Lilly).

The trial evaluated the pharmacodynamics and pharmacokinetics (PK) of BioChaperone Combo compared with a premix formulation of an insulin analog (Humalog Mix, lispro and protamine, Eli Lilly). Results showed that BioChaperone Combo provided both short- and long-term control of blood glucose in type I diabetic patients, with a faster onset and a longer duration of action. Both formulations were well tolerated and did not induce any local reaction.

Tim Heise, medical doctor and CEO of Profil, said in a press release that based on the positive results, single daily injection was possible with BioChaperone Combo and the treatment simplification provided by the combination insulin formulation offers convenience for patients requiring at least two injections per day of premix, or one of Lantus plus at least one of a fast-acting insulin.

The BioChaperone technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and the ease of use for patients. Eight patent applications have been submitted for its combination insulin formulation.

Source: Adocia

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here